Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids

Rheumatology (United Kingdom)

Volumn 52, Issue 6, 2013, Pages 1058-1069

  Devogelaer, Jean Pierre ^a   Sambrook, Philip ^b   Reid, David M ^c   Goemaere, Stefan ^d   Ish Shalom, Sophia ^e   Collette, Julien ^f   Su, Guoqin ^g   Bucci Rechtweg, Christina ^g   Papanastasiou, Philemon ^g   Reginster, Jean Yves ^h  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e RAMBAM MEDICAL CENTER   (Israel)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g NOVARTIS PHARMA AG   (Switzerland)

^h UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Bone turnover markers; Glucocorticoid induced osteoporosis; Glucocorticoids; Risedronate; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; PLACEBO; PREDNISONE; PROCOLLAGEN C PROTEINASE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOLYSIS; OSTEOPOROSIS; PARALLEL DESIGN; PATIENT PREFERENCE; POST HOC ANALYSIS; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

BONE TURNOVER MARKERS; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; GLUCOCORTICOIDS; RISEDRONATE; ZOLEDRONIC ACID;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETIDRONIC ACID; FEMALE; GLUCOCORTICOIDS; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OSTEOPOROSIS; PREDNISONE; TREATMENT OUTCOME;

EID: 84878143064     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes410     Document Type: Article

References (45)

1. Van Staa TP, Abenhaim L, Cooper C et al. The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 2000;9:359-66.
2. Doga M, Mazziotti G, Bonadonna S et al. Prevention and treatment of glucocorticoid-induced osteoporosis. J Endocrinol Invest 2008;31(Suppl 7):53-8.
3. Devogelaer JP. Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach. Rheum Dis Clin North Am 2006;32:733-57.
4. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008;20:131-7.
5. Hayashi K, Yamamoto M, Murakawa Y et al. Bone fragility in male glucocorticoid-induced osteoporosis is not defined by bone mineral density. Osteoporos Int 2009;20: 1889-94.
6. Angeli A, Guglielmi G, Dovio A et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006;39:253-9.
7. Naganathan V, Jones G, Nash P et al. Vertebral fracture risk with long term corticosteroids: prevalence, relationship to age, bone density and corticosteroid use. Arch Intern Med 2000;160:2917-22.
8. Yeap SS, Hosking DJ. Management of corticosteroid-induced osteoporosis. Rheumatology 2002;41:1088-94.
9. Hart SS, Green B. Osteoporosis prophylaxis during corticosteroid treatment: failure to prescribe. Postgrad Med J 2002;78:242-3.
10. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001;44:1496-503.
11. Homik JE, Cranney A, Shea B et al. A meta analysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 1999;26:1148-57.
12. Cohen S, Levy RM, Keller M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18.
13. Adachi JD, Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving GC: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44:202-11.
14. Reid DM, Hughes RA, Laan RF et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000;15:1006-13.
15. Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-9.
16. Sambrook PN, Kotowicz M, Nash P et al. Prevention and treatment of glucocorticoid induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium and alendronate plus calcium. J Bone Miner Res 2003;18: 919-24.
17. Craig SJ, Youssef PP, Vaile JH et al. Intravenous zoledronate and oral alendronate in patients with a low trauma fracture-experience from an osteoporosis clinic. Intern Med J 2010;41:139-215.
18. Seeman E, Compston J, Adachi J et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int 2007;18:711-9.
19. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
20. Lyles KW, Coló n-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809.
21. Boonen S, Sellmeyer DE, Lippuner K et al. Renal safety of annual zoledronic acid infusions in osteoporotic post-menopausal women. Kidney Int 2008;74: 641-8.
22. Recknor C. Zoledronic acid for prevention and treatment of osteoporosis. Expert Opin Pharmacother 2011;12: 807-15.
23. Jansen JP, Bergman GJ, Huels J et al. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 2011;40: 275-84.
24. Akehurst R, Brereton N, Ariely R et al. The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fracture: evidence from Finland, Norway and the Netherlands. J Med Econ 2011;14:53-64.
25. Bergmann P, Body JJ, Boonen S et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis. Int J Clin Pract 2009;63: 19-26.
26. Reginster JY, Collette J, Neuprez A et al. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 2008;42: 832-36.
27. Minisola S, Del Fiacco R, Piemonte S et al. Biochemical markers in glucocorticoid-induced osteoporosis. J Endocrinol Invest 2008;31:28-32.
28. Reid DM, Devogelaer J-P, Saag K et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373:1253-63.
29. Jaffe M. Ueber den niederschlag, welchen picrinsaure in normalen harn erzeugt und eine neue reaction des kreatinins. Hoppe Seylers Z Physiol Chem 1886;10: 391-400.
30. Foster-Swanson A, Swartzentruber M, Roberts P et al. Reference interval studies of the rate-blanked creatinine/ Jaffe method on BM/Hitachi systems in six US laboratories [abstract]. Clin Chem 1994;40:1057.
31. Gough AK, Lilley J, Eyre S et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344: 23-7.
32. Pearce G, Ryan PFJ, Delmas PD et al. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol 1998;37:292-9.
33. Orwoll ES, Miller PD, Adachi JD et al. Efficacy and safety of a once-yearly IV infusion of zoledronic acid 5mg versus a once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010;25:2239-50.
34. MacDonald AG, Birkinshaw G, Durham B et al. Biochemical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity. Br J Rheumatol 36:50-3.
35. McClung M, Miller P, Recknor C et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009;114:999-1007.
36. Sornay-Rendu E, Munoz F, Garnero P et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005;20:1813-9.
37. Wainwright SA, Marshall LM, Ensrud KE et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005;90:2787-93.
38. Drake WM, Kendler DL, Rosen CJ et al. An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. J Clin Endocrinol Metab 2003;88:5759-65.
39. Lenora J, Ivaska KK, Obrant KJ et al. Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 2007;18:1297-305.
40. Rogers A, Hannon RA, Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 2000;15:1398-404.
41. Garnero P, Munoz F, Sornay-Rendu E et al. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone 2007;40: 716-22.
42. Eastell R, Black DM, Boonen S et al. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 2009;94:3215-25.
43. Boonen S, Black MD, Colon-Emeric SC et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010;58:292-9.
44. McClung M, Recker R, Miller P et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007;41: 122-8.
45. Saag K, Lindsay R, Kriegman A et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007;40: 1238-43.